One of the most dreaded feelings for an investor is when the stock they just bought is overvalued, or they missed out on an undervalued opportunity by not acting fast enough.

But what if you had the insights to effectively evaluate a company like Corcept Therapeutics Incorporated before investing? Investing requires a certain perspective to avoid being overly confident in a company or worried about cyclical changes. A smart way to take the guesswork out of knowing when to buy or sell Corcept Therapeutics Incorporated’s stock is to have the right tools and resources as well as a clear monitoring process.

In this article, we go over a few key elements for understanding Corcept Therapeutics Incorporated’s stock price such as:

• Current stock price and volume
• Stock price history
• Upgrades and downgrades from analysts
• Stock price momentum as measured by its relative strength

About Corcept Therapeutics Incorporated (CORT)

Before we jump into Corcept Therapeutics Incorporated’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company?s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.

Want to learn more about Corcept Therapeutics Incorporated’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Corcept Therapeutics Incorporated. The AAII Stock Evaluator puts a company’s grades, charts, news, financials, valuation, ratios, filings and more at your fingertips.

Corcept Therapeutics Incorporated’s Stock Price as of Market Close

As of September 07, 2023, 4:00 PM CST, Corcept Therapeutics Incorporated’s stock price was $33.15.

Corcept Therapeutics Incorporated is up 5.14% from its previous closing price of $31.53.

During the last market session, Corcept Therapeutics Incorporated’s stock traded between $31.06 and $31.97. Currently, there are 101.96 million shares of Corcept Therapeutics Incorporated stock available for purchase.

Corcept Therapeutics Incorporated’s price-earnings (P/E) ratio is currently at 38.1, which is high compared to the Pharmaceuticals industry median of 18.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Corcept Therapeutics Incorporated Stock Price History

Corcept Therapeutics Incorporated’s (CORT) price is currently up 1.28% so far this month.

During the month of September, Corcept Therapeutics Incorporated’s stock price has reached a high of $33.26 and a low of $31.06.

Over the last year, Corcept Therapeutics Incorporated has hit prices as high as $33.24 and as low as $17.86. Year to date, Corcept Therapeutics Incorporated’s stock is up 67.42%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Corcept Therapeutics Incorporated Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 06, 2023, there were 0 analysts who downgraded Corcept Therapeutics Incorporated’s stock and 6 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Corcept Therapeutics Incorporated’s financial health and valuation. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others.

Therefore, AAII developed a composite valuation to help resolve such issues. AAII’s Value Grade analyzes six distinct variables: price-to-sales (P/S) ratio, price-earnings (P/E) ratio, the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA), shareholder yield, price-to-book-value (P/B) ratio and price-to-free-cash-flow (P/FCF) ratio.

Corcept Therapeutics Incorporated’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Corcept Therapeutics Incorporated (CORT) by visiting AAII Stock Evaluator.

Relative Price Strength of Corcept Therapeutics Incorporated

Relative price strength addresses the relationship between a stock price’s trend and the price trend of the market. This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. The weighted four-quarter relative price strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40%, and each of the three previous quarters are given a weighting of 20%.

As of September 06, 2023, Corcept Therapeutics Incorporated has a weighted four-quarter relative price strength of 7.55%, which translates to a Momentum Score of 86 and is considered to be Very Strong.

Want to learn more about how Corcept Therapeutics Incorporated is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Corcept Therapeutics Incorporated Stock Price: Bottom Line

As of September 7, 2023, Corcept Therapeutics Incorporated’s stock price is $33.15, which is up 5.14% from its previous closing price.

At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics before making a decision. Whether you decide it’s a good time to buy or sell Corcept Therapeutics Incorporated’s stock based on its stock price forecast is ultimately up to you.

It’s important to understand that stock prices are driven by a variety of factors, but ultimately the price at any given moment is due to the supply and demand in the market. Stock price overviews, like the one you just read, only give you a small snapshot of a company’s performance, value and momentum.

By becoming an A+ Investor subscriber, you will have full access to analytics, grades, stock screens, commentary and more so you can invest with confidence.